V. Narry Kim (Korean: 김빛내리; born 18 June 1969) is a South Korean biochemist and microbiologist, best known for her work on microRNA biogenesis. Her pioneering studies have laid the groundwork for the biology of microRNA and contributed to the improvement of RNA interference technologies.
Background Kim was born in South Korea in 1969. Kim first became interested in science as a high school student. When asked why she chose science as a lifelong career, she said, “I was charmed by the simplicity of the principles underlying the complexity of life.”
Education Kim went on to pursue a BA degree in microbiology, then followed by a MS degree in microbiology in 1992 and 1994, respectively, both from Seoul National University (SNU). After completing her masters under adviser Kang Sa-Ouk, Kim went to the United Kingdom to further her studies at the University of Oxford, studying the functions of retroviral proteins under Alan J. Kingsman. She graduated with a PhD in biochemistry in 1998.
Career Her academic journey then took her to the United States, where she took a position at the Howard Hughes Medical Institute at the University of Pennsylvania in Philadelphia as a research assistant. After completing her postdoctoral research on mRNA surveillance in the laboratory of Gideon Dreyfuss, Kim finished her postdoctoral studies and returned to Korea in 2001. She then started working at Seoul National University as a research assistant professor. By the age of 35, Kim already had twenty-two of her papers published in well known and prestigious scientific publications, such as Science and Nature. In addition, Kim “holds four patents based on her research activities, including one on a novel HIV-based gene delivery vector.” In 2008, she became an associate professor, then a SNU Distinguished Fellow in 2010, and a full professor in 2013. Located in Seoul National University, she began working with the Institute for Basic Science (IBS) in 2012 as the founding director of the Center for RNA Research. her lab focuses on RNA-mediated gene regulation research, specifically investigating post-transcriptional gene regulation mediated by microRNAs (miRNAs). The lab employs biochemistry, molecular biology, genetic, biophysical, and computational approaches. Research is focused on miRNAs, which are small non-coding RNAs involved in practically all working aspects of eukaryotic cells. Tight control of miRNA is vital to normal functioning cells. If dysregulated, miRNAs can often be linked to human diseases such as cancer. By focusing on the miRNA biogenesis, Dr. Kim's lab has made major contributions to the understanding of miRNAs are created and processed in animal cells. These studies can potentially open the doors to new forms of cancer treatment and stem cell engineering. In 2013, Kim, along with Professor Jin-Soo KIM of the SNU Department of Chemistry developed a new technology to eliminate specific microRNAs. This new technology has the promise of being potentially used to cure cancer and other illnesses in the future. In the research, TALENs (enzymes) were used to separate certain microRNA from a cell. TALENs had been used to create protein before, but this was the first time they have been used to separate microRNA. The team developed 540 different TALENs for this specific purpose. When this was applied to cancer cells, the proliferation rate of cancer cells dropped to one third of what it was. This discovery was published in the November 11, 2013 edition of Nature Structural and Molecular Biology. Kim's first paper as PI was published in 2002 in the EMBO Journal. In this highly cited work, she defined two separate processing steps (primary microRNA (pri-miRNA) processing in the nucleus and pre-miRNA processing in the cytoplasm), and proposed a model of the microRNA biogenesis pathway for the first time. Based on this model, her research group discovered that most microRNA genes are transcribed by RNA polymerase II and that pri-miRNA processing is carried out by Drosha-DGCR8 complexes in the nucleus. Her research group further identified uridylation-meditated pre-miRNA degradation pathway by LIN28 and TUT4, contributing to a better understanding of how microRNA-mediated gene expression regulation is involved in embryonic stem cell maintenance and cancer cell development. She also discovered the molecular basis for pri-miRNA recognition and cleavage by the Drosha-DGCR8 complexes, and pre-miRNA processing by Dicer. These findings suggested several critical points to be considered for designing more efficient short hairpin RNA (shRNA) vectors and also contributed to the improvement of RNA interference technologies. The research team led by Narry Kim and Chang Hyeshik confirmed the predicted subgenomic RNAs of SARS-CoV-2 along with new RNA and dozens of unknown subgenomic RNAs. The interdisciplinary team was composed of virologists, microbiologists and computational scientists. Kim received L'Oreal-UNESCO Award for Women in Science (2008), Ho-Am Prize in Medicine (2009) and Top Scientist and Technologist Award of Korea (2013). She is an active member of the RNA Society and the International Society of Stem Cell Research (ISSCR). In addition she has been recognized as one of the top Asian scientists to watch by Asian Scientist and among the "science stars of East Asia" by Nature. She was a Clarivate Analytics Highly Cited Researcher in the field of molecular biology and genetics in 2014.
Work summary
Professional experience:
2013–present: Professor, Seoul National University 2012–present: Director, Center for RNA Research, Institute for Basic Science 2010–present: SNU Distinguished Fellow, Seoul National University 2008–2013: Associate Professor, Seoul National University 2004–2008: Assistant Professor, Seoul National University 2001–2004: Research Assistant Professor, Seoul National University 1999–2001: Postdoctoral fellow, Howard Hughes Medical Institute, University of Pennsylvania (with Gideon Dreyfuss) Professional service:
… excerpt ends here. Continue reading the full article.
